Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

NK cells are biologic and biochemical targets of 6-mercaptopurine in Crohn's disease patients.

Yusung S, McGovern D, Lin L, Hommes D, Lagishetty V, Braun J.

Clin Immunol. 2016 Dec 21;175:82-90. doi: 10.1016/j.clim.2016.12.004. [Epub ahead of print]

PMID:
28011186
3.

Analysis of protein-coding genetic variation in 60,706 humans.

Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG; Exome Aggregation Consortium..

Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.

PMID:
27535533
4.

Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.

Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ.

Curr Med Res Opin. 2016 Dec;32(12):1937-1941.

PMID:
27494777
5.

Outcomes with Anti-Tumour Necrosis Factor-Alpha Therapy and Serology in Patients with Denovo Crohn's Disease After Ileal Pouch Anal Anastomosis.

Robbins L, Zaghiyan K, Melmed G, Vasiliauskas E, Ahmed S, McGovern D, Rabizadeh S, Singh N, Landers C, Ippoliti A, Shih D, Targan S, Fleshner P.

J Crohns Colitis. 2017 Jan;11(1):77-83. doi: 10.1093/ecco-jcc/jjw134.

PMID:
27466172
6.

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD.

J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.

7.

O-015 YI Alterations in the FOXP3-EZH2 Pathway Associates with Increased Susceptibility to Colitis in Both Mice and Human.

Sarmento O, Xiong Y, Sun Z, Svingen P, Bamidele A, Smyrk T, Nair A, Baheti S, McGovern D, Friton J, Papadakis K, Goel G, Xavier R, Urrutia R, Faubion W.

Inflamm Bowel Dis. 2016 Mar;22 Suppl 1:S5-6. doi: 10.1097/01.MIB.0000480101.02647.09.

PMID:
26849732
8.

O-011 Paneth Cell Phenotypes Define a Subtype of Pediatric Crohn's Disease Through Alterations in Host-Microbial Interactions.

Liu TC, Gurram B, Baldridge M, Head R, Lam V, Luo C, Cao Y, Simpson P, Hayward M, Holtz M, Noe J, Lerner D, Cabrera J, Biank V, Stephens M, Huttenhower C, McGovern D, Xavier R, Stappenbeck T, Salzman N.

Inflamm Bowel Dis. 2016 Mar;22 Suppl 1:S4. doi: 10.1097/01.MIB.0000480097.23732.5e.

PMID:
26849729
9.

O-004 Analysis of Chromatin and Transcriptional Profiles in Crohn's Disease Reveals Molecular Subclasses and Highlights Functional Regulatory Regions Implicated in Disease.

Weiser M, Sheikh S, Kochar B, Gipson G, Herfarth H, Sartor R, McGovern D, Rahbar R, Sadiq T, Furey T, Koruda M, Robinson A.

Inflamm Bowel Dis. 2016 Mar;22 Suppl 1:S1-2. doi: 10.1097/01.MIB.0000480042.88631.e4.

PMID:
26849721
10.

O-002 Genes in IBD-Associated Risk Loci Demonstrate Genotype-, Tissue-, and Inflammation-Specific Patterns of Expression in Terminal Ileum and Colon Mucosal Tissue.

Peloquin J, Goel G, Huang H, Haritunians T, Sartor R, Daly M, Newberry R, McGovern D, Lira S, Xavier R.

Inflamm Bowel Dis. 2016 Mar;22 Suppl 1:S1. doi: 10.1097/01.MIB.0000480040.50582.81.

PMID:
26849719
11.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A.

Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006.

12.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD.

Ann Oncol. 2016 Apr;27(4):648-53. doi: 10.1093/annonc/mdw020.

13.

Nonbloody Diarrhea but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulcerative Colitis.

Ahmed S, Melmed G, McGovern D, Robbins LA, Shih D, Vasiliauskas E, Singh N, Rabidzadeh S, Ippoliti A, Targan S, Fleshner P.

Inflamm Bowel Dis. 2016 Mar;22(3):654-61. doi: 10.1097/MIB.0000000000000630.

PMID:
26595552
14.

A novel role for KLF14 in T regulatory cell differentiation.

Sarmento OF, Svingen PA, Xiong Y, Xavier RJ, McGovern D, Smyrk TC, Papadakis KA, Urrutia RA, Faubion WA.

Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):188-202.e4.

15.

Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States.

Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS.

Clin Gastroenterol Hepatol. 2015 Jun;13(6):1197-200. doi: 10.1016/j.cgh.2014.11.020.

16.

Molecular patterns in human ulcerative colitis and correlation with response to infliximab.

Halloran B, Chang J, Shih DQ, McGovern D, Famulski K, Evaschesen C, Fedorak RN, Thiesen A, Targan S, Halloran PF.

Inflamm Bowel Dis. 2014 Dec;20(12):2353-63. doi: 10.1097/MIB.0000000000000239.

17.

Should biologic agents be stopped before surgery for inflammatory bowel disease?

Zaghiyan K, McGovern D, Fleshner P.

Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):269-72. doi: 10.1586/17474124.2015.975208. Review.

PMID:
25366845
18.

Personalized Medicine in Inflammatory Bowel Disease.

McGovern D.

Gastroenterol Hepatol (N Y). 2014 Oct;10(10):662-4. No abstract available.

19.

Decellularized tracheal extracellular matrix supports epithelial migration, differentiation, and function.

Kutten JC, McGovern D, Hobson CM, Luffy SA, Nieponice A, Tobita K, Francis RJ, Reynolds SD, Isenberg JS, Gilbert TW.

Tissue Eng Part A. 2015 Jan;21(1-2):75-84. doi: 10.1089/ten.TEA.2014.0089.

20.

The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.

Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P.

Ann Surg. 2015 Mar;261(3):487-96. doi: 10.1097/SLA.0000000000000757.

Items per page

Supplemental Content

Loading ...
Support Center